Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis

Abstract

Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance. Bone morphogenic proteins (BMPs) represent possible candidates as they inhibit proliferation, stimulate bone formation and have an effect on the survival of cancer patients. We assessed the expression of BMPs and their receptors by Affymetrix DNA microarrays (n=779) including CD138-purified primary myeloma cell samples (n=635) of previously untreated patients. BMP6 is the only BMP expressed by malignant and normal plasma cells. Its expression is significantly lower in proliferating myeloma cells, myeloma cell lines or plasmablasts. BMP6 significantly inhibits the proliferation of myeloma cell lines, survival of primary myeloma cells and in vitro angiogenesis. A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, β2 microglobulin).

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Barlogie B, Tricot G, Rasmussen E, Anaissie E, van RF, Zangari M et al. (2006). Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 107: 2633–2638.

    Article  CAS  PubMed  Google Scholar 

  • Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. (1998). Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  • Caplan AI . (2007). Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213: 341–347.

    Article  CAS  PubMed  Google Scholar 

  • Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L et al. (2003). Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A: 1544–1552.

    Article  Google Scholar 

  • Clement JH, Sanger J, Hoffken K . (1999). Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80: 250–256.

    Article  CAS  PubMed  Google Scholar 

  • Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S et al. (2007). Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21: 1079–1088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C et al. (2005). Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44: 194–203.

    Article  CAS  PubMed  Google Scholar 

  • Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET . (2005). Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65: 8274–8285.

    Article  CAS  PubMed  Google Scholar 

  • De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC et al. (2001). Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98: 771–780.

    Article  CAS  PubMed  Google Scholar 

  • De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K et al. (2006). Microarray-based understanding of normal and malignant plasma cells. Immunol Rev 210: 86–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Du J, Yang S, Wang Z, Zhai C, Yuan W, Lei R et al. (2007). Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways. J Cell Biochem 103: 1584–1597.

    Article  Google Scholar 

  • Durie BG . (1986). Staging and kinetics of multiple myeloma. Semin Oncol 13: 300–309.

    CAS  PubMed  Google Scholar 

  • Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M et al. (1999). Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112: 3519–3527.

    CAS  PubMed  Google Scholar 

  • Goldschmidt H, Sonneveld P, Cremer FW, van der HB, Westveer P, Breitkreutz I et al. (2003). Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82: 654–659.

    Article  CAS  PubMed  Google Scholar 

  • Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. (2005). International staging system for multiple myeloma. J Clin Oncol 23: 3412–3420.

    Article  PubMed  Google Scholar 

  • Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN . (1997). Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 57: 4427–4431.

    CAS  PubMed  Google Scholar 

  • Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH . (2004). Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64: 8276–8284.

    Article  CAS  PubMed  Google Scholar 

  • Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S et al. (2006). Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107: 4484–4490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A et al. (2009a). Induction of angiogenesis by normal and malignant plasma cells. Blood 114: 128–143.

    Article  CAS  PubMed  Google Scholar 

  • Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J et al. (2009b). Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113: 4331–4340.

    Article  CAS  PubMed  Google Scholar 

  • Irie A, Habuchi H, Kimata K, Sanai Y . (2003). Heparan sulfate is required for bone morphogenetic protein-7 signaling. Biochem Biophys Res Commun 308: 858–865.

    Article  CAS  PubMed  Google Scholar 

  • Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF et al. (1998). The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 100: 637–646.

    Article  CAS  PubMed  Google Scholar 

  • Kawabata M, Imamura T, Miyazono K . (1998). Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9: 49–61.

    Article  CAS  PubMed  Google Scholar 

  • Kersten C, Dosen G, Myklebust JH, Sivertsen EA, Hystad ME, Smeland EB et al. (2006). BMP-6 inhibits human bone marrow B lymphopoiesis—upregulation of Id1 and Id3. Exp Hematol 34: 72–81.

    Article  CAS  PubMed  Google Scholar 

  • Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH . (2005). BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol 6: 9.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim IY, Lee DH, Lee DK, Kim BC, Kim HT, Leach FS et al. (2003). Decreased expression of bone morphogenetic protein (BMP) receptor type II correlates with insensitivity to BMP-6 in human renal cell carcinoma cells. Clin Cancer Res 9: 6046–6051.

    CAS  PubMed  Google Scholar 

  • Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E et al. (2003). Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78: 106–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kochanowska I, Chaberek S, Wojtowicz A, Marczynski B, Wlodarski K, Dytko M et al. (2007). Expression of genes for bone morphogenetic proteins BMP-2, BMP-4 and BMP-6 in various parts of the human skeleton. BMC Musculoskelet Disord 8: 128.

    Article  PubMed  PubMed Central  Google Scholar 

  • Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A et al. (2003). Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 278: 24113–24117.

    Article  CAS  PubMed  Google Scholar 

  • Kyle RA, Rajkumar SV . (2004). Multiple myeloma. N Engl J Med 351: 1860–1873.

    Article  CAS  PubMed  Google Scholar 

  • Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J et al. (2006). Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25: 7180–7191.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E et al. (2007). Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 109: 4914–4923.

    Article  CAS  PubMed  Google Scholar 

  • Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J et al. (2005). Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24: 3512–3524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Massague J . (2000). How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1: 169–178.

    Article  CAS  PubMed  Google Scholar 

  • Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P et al. (2005). The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106: 1021–1030.

    Article  CAS  PubMed  Google Scholar 

  • Nohe A, Keating E, Knaus P, Petersen NO . (2004). Signal transduction of bone morphogenetic protein receptors. Cell Signal 16: 291–299.

    Article  CAS  PubMed  Google Scholar 

  • Ren R, Charles PC, Zhang C, Wu Y, Wang H, Patterson C . (2007). Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109: 2847–2853.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O et al. (2004). Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23: 3024–3032.

    Article  PubMed  Google Scholar 

  • Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V et al. (2002). Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood 100: 1113–1122.

    CAS  PubMed  Google Scholar 

  • Trojan A, Tinguely M, Vallet S, Seifert B, Jenni B, Zippelius A et al. (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly 136: 400–403.

    CAS  PubMed  Google Scholar 

  • Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F et al. (1994). Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87: 503–508.

    Article  CAS  PubMed  Google Scholar 

  • Valdimarsdottir G, Goumans MJ, Rosendahl A, Brugman M, Itoh S, Lebrin F et al. (2002). Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation 106: 2263–2270.

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE, Timm M, Larson D, Therneau T, Greipp PR . (1999). Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 104: 131–137.

    Article  CAS  PubMed  Google Scholar 

  • Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C et al. (2006). Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77: 75–83.

    Article  PubMed  Google Scholar 

  • Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E et al. (2002). Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99: 1745–1757.

    Article  CAS  PubMed  Google Scholar 

  • Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M et al. (1994). Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83: 3654–3663.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Katrin Heimlich, Maria Dörner and Gabriele Hoock for technical assistance. This work was supported in part by grants from the Hopp-Foundation (Germany), the University of Heidelberg (Germany), the National Centre for Tumor Diseases (Heidelberg, Germany), the Tumorzentrum Heidelberg/Mannheim (Germany), the European Myeloma Stem Cell Network (MSCNET) funded within the 6th framework program of the European Community, Novartis Pharma GmbH (Nuremberg, Germany), the Ligue Nationale Contre Le Cancer (équipe labellisée) (Paris, France). It is also part of a national program called ‘Carte d’Identité des Tumeurs' (CIT) funded by the Ligue Nationale Contre le Cancer (France).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D Hose.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Seckinger, A., Meißner, T., Moreaux, J. et al. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28, 3866–3879 (2009). https://doi.org/10.1038/onc.2009.257

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2009.257

Keywords

This article is cited by

Search

Quick links